Hello Avatar! Welcome to the BowtiedBiotech podcast, where science meets business! If you're fascinated by breakthrough biotech, bold innovations, and the business behind the science, you're in the right place. Each week, we dive into the world of biotech with fresh insights, sharp analysis, and the stories that are shaping the future of health. Whether you’re an industry insider, an investor, or just biotech-curious, we’ve got something for you.
We are now publishing 7x per week according to the following cadence:
Mondays: BioBucks: Stock Analysis & Biotech Catalysts
Tuesdays: X-article on biotech hot topics
Wednesdays: Podcast format of X-article
Thursdays: Insiders Track: Public & Private Biotech Markets
Fridays: Sweat Equity: Your Weekly Biotech Fix
Saturdays: Podcast format of Weekly News Update
Sundays: Building Biotech: Strategic Topics
SUBSCRIBE TO PODCAST HERE:
Please help spread the work by subscribing and hitting the share button if you are enjoying content!
Welcome to the BowTied Biotech Podcast! Today, we’re diving into the biggest trends and stories that shaped biopharma in 2024. We’ll begin with the critical role of manufacturing and scaling in the industry’s evolution before exploring the cautious approach to IPOs and M&A this year. Next, we’ll tackle clinical setbacks like the ongoing debate around the amyloid hypothesis for Alzheimer’s and highlight breakthroughs such as molecular glue degraders and gut microbiome therapies in cancer treatment.
We’ll also examine industry resilience amid major layoffs, delve into Merck’s bold $2 billion move into obesity pills, and discuss advances in non-opioid painkillers. Closing out, we’ll look at exciting innovations in gene editing for sickle cell by Tessera, Sanofi/Teva’s promising IBD therapy, and Edgewise’s treatment for Becker muscular dystrophy. Finally, we’ll reflect on the lessons and optimism the year brought to biopharma. Stay tuned for an episode packed with insights and inspiration!
📣🎙️ TODAY’S POCAST
( 0:00 ) Introduction
( 0:32 ) 2024 Biopharma Trends: Manufacturing and Scaling
( 2:04 ) IPO and M&A Caution
( 3:46 ) Clinical Setbacks: The Amyloid Hypothesis
( 5:48 ) Breakthroughs: Molecular Glue Degraders
( 6:44 ) Gut Microbiome in Cancer Therapy
( 7:13 ) Industry Resilience Amid Layoffs
( 10:10 ) Merck’s Obesity Pill Strategy
( 12:08 ) Advances in Non-Opioid Painkillers
( 14:30 ) Gene Editing for Sickle Cell by Tessera
( 15:26 ) Sanofi/Teva’s IBD Drug Success
( 16:24 ) Becker Muscular Dystrophy Treatment by Edgewise
( 17:07 ) Final Reflections on Biopharma in 2024
CONCLUSION
We hope you are enjoying our first leap into the podcast world! Instead of waiting until everything is perfect, we’re diving in and will continue improving as we go. Feel free to send us your suggestions, feedback, or constructive criticism—we’d love to hear from you!
As a reminder, if looking to go deeper into the topics we cover check out our website BowTiedBiotech.com, or DM us on twitter, or email us: bowtiedbiotech@gmail.com
ABOUT BOWTIEDBIOTECH
As a reminder, the purpose of the BowTiedBiotech substack is two-fold. Primarily, we aim to provide our scientist audience the tools to build a biotech company and ultimately translate their ideas into medicines for patients. Secondarily, biotech investors may find this substack useful as we will be providing weekly market updates of the public AND private markets as well as heavily leveraging current financing events as teaching examples.
DISCLAIMER
None of this is to be deemed legal or financial advice of any kind. All updates are sourced from publicly available disclosures. Insights are *opinions* written by an anonymous cartoon/scientist/investor.
TOP BOWTIEDBIOTECH NEWSLETTERS
Share this post